| Literature DB >> 36071401 |
Yongjie Sha1, Chunyan Li2, Yuan Xiong1, Aniruddha Hazra3, Jonathan Lio3, Ivy Jiang3, Haojie Huang4, Jared Kerman3, Jannelle Molina5, Linghua Li6, Ke Liang7, Dandan Gong6, Quanmin Li6, Songjie Wu7, Renslow Sherer8, Joseph D Tucker9,10,11, Weiming Tang12,13.
Abstract
BACKGROUND: Adherent pre-exposure prophylaxis (PrEP) uptake can prevent HIV infections. Despite the high HIV incidence, Chinese key populations have low PrEP uptake and adherence. New interventions are needed to increase PrEP adherence among key populations in China. Co-creation methods are helpful to solicit ideas from the community to solve public health problems. The study protocol aims to describe the design of a stepped-wedge trial and to evaluate the efficacy of co-created interventions to facilitate PrEP adherence among key populations in China.Entities:
Keywords: Adherence; China; Co-creation; GBMSM; PrEP; Randomized controlled trial; Stepped-wedge design; Transgender
Mesh:
Year: 2022 PMID: 36071401 PMCID: PMC9449927 DOI: 10.1186/s12889-022-14117-5
Source DB: PubMed Journal: BMC Public Health ISSN: 1471-2458 Impact factor: 4.135
Stepped-wedge design of a crowdsourced intervention for facilitating PrEP adherence in at-risk populations in China
Fig. 1Schematic of crowdsourcing intervention development and implementation
Outcome measures and timepoints of data collection
| Outcomes | Measure | Data collection timepoints |
|---|---|---|
| | Number of participants completed clinical follow-ups | 3, 6, 9, 12 months |
| | 1. Self-report in follow-up surveys: During the past 7 days and 30 days: (1) self-report taking once daily regimen: number of missed pills; perceptions of whether they had taken < 60%, 60–90%, or > 90% doses. (2) self-report taking on-demand regimen: number of sex events that are not covered by any PrEP (0 pills taken); correctly covered by PrEP (2 pills on the sex day (X) and X + 1, X + 2; or at least one pill taken on days X, X + 1, and X + 2 if the days between two sex events are less than one week); partially covered by PrEP (any other use). 2. Pill count at clinical visits: number of unused pills counted at each clinical follow-up (in-person or via phone) 3. Medical possession ratio: [(total days between first fill and end of follow-up) – (number of days without TDF-FTC in possession)] / total days of follow-up, based on medical refilling records | 3, 6, 9, 12 months |
| | 120 days without TDF-FTC in possession based on medical refilling records. | 3, 6, 9, 12 months |
| | Number of participants who discontinued TDF-FTC according to the study definition and then successfully restart PrEP, based on self-report and medical refilling records. | 3, 6, 9, 12 months |
| | Frequency of participants, defined as the number of participants who reported being tested for HIV during the previous three months | 3, 6, 9, 12 months |
| | Frequency of participants, defined as the number of participants who reported using the mini-app in the past three months to receive information about sexual and mental health comparing their pre-intervention and post-intervention engagement | 3, 6, 9, 12 months |
| | Frequency of participants, defined as number of participants who had an increase in PrEP self-efficacy when comparing their pre-intervention and post-intervention self-efficacy | 3, 6, 9, 12 months |
| | Frequency of participants, defined as number of participants who reported who have newly diagnosed with HIV in the previous three months | 3, 6, 9, 12 months |